These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: CD23 expression in transformed small lymphocytic lymphomas/chronic lymphocytic leukemias and blastic transformations of mantle cell lymphoma.
    Author: Dunphy CH, Wheaton SE, Perkins SL.
    Journal: Mod Pathol; 1997 Aug; 10(8):818-22. PubMed ID: 9267825.
    Abstract:
    The immunophenotypic marker, CD23, has been shown to be a useful marker for the distinction of small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) from mantle cell lymphoma (MCL). The usefulness of this marker has not previously been analyzed in distinguishing various "large cell" transformations of SLL/CLL from blastic transformations of MCL (MCL-B). Thirteen cases of transformed SLL/CLL and six cases of MCL-B were analyzed for expression of CD23, either by flow cytometry of peripheral blood, bone marrow, or fresh tissue or by immunoperoxidase staining of paraffin-embedded archival tissue. All of the 13 cases of transformed SLL/ CLL expressed CD23 and all of the 6 cases of MCL-B were negative for CD23. Therefore, CD23 is retained in transformed SLL/CLL. It is a useful marker in distinguishing transformed SLL/CLL from MCL-B and thus might aid in distinguishing those cases that present de novo without a previous diagnosis of SLL/CLL or MCL.
    [Abstract] [Full Text] [Related] [New Search]